Your email has been successfully added to our mailing list.

×
-0.301168831168831 -0.597402597402597 -0.727272727272727 -0.675324675324675 -0.74025974025974 -0.712987012987013 -0.701298701298701 -0.701298701298701
Stock impact report

Aevi Genomic Medicine Announces Top-Line Results from Placebo-Controlled ASCEND Trial (Parts A & B) of AEVI-001 in Children with ADHD

AEVI GENOMIC MEDICINE INC (GNMX) 
Last aevi genomic medicine inc earnings: 11/14 08:01 am Check Earnings Report
US:NASDAQ Investor Relations: aevigenomics.com
Company Research Source: PR Newswire
PHILADELPHIA, Jan. 2, 2019 /PRNewswire/ -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) ("the Company") today announced that the ASCEND trial, a genomically-guided Phase 2 double-blind, placebo-controlled clinical trial of orally-administered AEVI-001 (100 – 400 mg BID) in children aged 6 – 17 with Attention Deficit Hyperactivity Disorder (ADHD) with an mGluR copy number variant (Part A) or without an mGluR copy number variant (Part B), did not achieve statistical significance on the primary endpoint of reduction of ADHD-RS in either Part A or Part B after 6 weeks of treatment with AEVI-001.  AEVI-001 was safe and well tolerated. Reported adverse events were minimal and similar across both Part A and Part B treatment groups."We are very disappointed that the ASCEND trial did not achieve its primary endpoint," said Michael F. Cola, CEO of Aevi Genomic Medicine.  "We plan to conduct a full review of the data with our scientific advisers in the coming days and consider our options.  We wan Show less Read more
Impact Snapshot
Event Time:
GNMX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for GNMX alerts
Opt-in for
GNMX alerts

from News Quantified
Opt-in for
GNMX alerts

from News Quantified